Recombinant Human ERCC5, N-His

Description of Recombinant Human ERCC5, N-His

Introduction

Recombinant Human ERCC5, N-His is a protein that plays a crucial role in DNA repair and maintenance. It is a drug target for various diseases and has been extensively studied for its structure, activity, and potential applications.

Structure of Recombinant Human ERCC5, N-His

Recombinant Human ERCC5, N-His is a 133 kDa protein that belongs to the DNA excision repair protein family. It is composed of 1180 amino acids and has a conserved helicase domain at its N-terminus. The protein also contains a C-terminal region that is involved in protein-protein interactions.

The crystal structure of Recombinant Human ERCC5, N-His has been determined, revealing a complex architecture with multiple domains. The N-terminal helicase domain consists of seven helicase motifs, which are essential for the protein’s DNA unwinding activity. The C-terminal region contains a zinc-binding domain and a leucine zipper motif, which are involved in protein-protein interactions.

Activity of this protein

Recombinant Human ERCC5, N-His is a DNA helicase that plays a crucial role in the nucleotide excision repair (NER) pathway. This pathway is responsible for repairing damaged DNA, such as UV-induced lesions, chemical adducts, and cross-links. ERCC5, N-His is involved in the later stages of the NER pathway, where it unwinds the damaged DNA strand to allow for the removal of the damaged segment.

Apart from its role in DNA repair, Recombinant Human ERCC5, N-His has also been found to have transcriptional activity. It interacts with various transcription factors and co-activators, suggesting a potential role in gene regulation.

Applications of Recombinant Human ERCC5, N-His

Recombinant Human ERCC5, N-His has been identified as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and premature aging syndromes. Its role in DNA repair and transcriptional regulation makes it an attractive target for developing novel therapies.

In cancer, mutations in the ERCC5 gene have been linked to increased risk and poor prognosis in various types of cancer, including lung, breast, and ovarian cancer. Targeting Recombinant Human ERCC5, N-His could potentially inhibit cancer cell growth and sensitize them to chemotherapy.

In neurodegenerative disorders, such as Parkinson’s and Alzheimer’s disease, DNA damage has been implicated in disease progression. Recombinant Human ERCC5, N-His could play a crucial role in repairing this damage and potentially slowing down the disease’s progression.

Furthermore, Recombinant Human ERCC5, N-His has also been investigated as a potential target for premature aging syndromes, such as xeroderma pigmentosum and Cockayne syndrome. These syndromes are characterized by defects in DNA repair, and targeting Recombinant Human ERCC5, N-His could potentially provide a therapeutic approach.

Conclusion

In summary, Recombinant Human ERCC5, N-His is a crucial protein involved in DNA repair and transcriptional regulation. Its structure and activity have been extensively studied, and it has been identified as a potential drug target for various diseases. Further research on this protein could lead to the development of novel therapies for cancer, neurodegenerative disorders, and premature aging syndromes.